Antibody Bioavailability Drug Delivery Systems RNA 
Roots Analysis
MAY 21, 2024
Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.
XTalks
AUGUST 30, 2022
A major obstacle for CNS drug developers is the inability to target therapies to the CNS broadly (for instance, a therapy that is orally bioavailable as a pill and has difficulty crossing the blood-brain barrier) and certain CNS regions more specifically. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets?
Expert insights. Personalized for you.
40 
Let's personalize your content